DCAL Dishman Carbogen Amcis Q3 FY26 results (Oct–Dec 2025) and concall
Dishman Carbogen reported a mixed Q3 FY26, with revenue growth of 5.5% but a net loss, partly due to delayed shipments expected in Q4 and higher commercial supply costs. However, the nine-month performance showed robust EBITDA growth and margin expansion. Management expressed strong confidence in future growth, driven by strategic integration, capacity ramp-up across global sites, and a strong pipeline in CDMO and Marketable Molecules, with clear targets for revenue and profitability improvement.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 58.8%, net profit down 76.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 93 | 97 | 106 | 63 | 60 −35% | 40 −59% |
| EBITDA | 13 | 23 | 21 | 3 | 4 −69% | -4 −117% |
| Net profit | 14 | -13 | -7 | 3 | -14 −200% | -23 −77% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
